Actively Recruiting
Phase III Study Evaluating VC005 Tablets in Adults Aged 18 to 75 with Moderate to Severe Atopic Dermatitis
Led by Jiangsu vcare pharmaceutical technology co., LTD · Updated on 2026-07-27
480
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This clinical trial is a multicenter, randomized, double-blind, controlled phase III study evaluating VC005 tablets in adults with moderate to severe atopic dermatitis. The study aims to assess the treatment effects of VC005 in patients aged 18 to 75 years who have had atopic dermatitis symptoms for at least one year and who meet specific severity criteria based on clinical scores. Participants are randomly assigned to one of three groups VC005 low dose, VC005 high dose, or placebo. The study involves repeated administration of the assigned treatment, with dosing details and schedules managed under double-blind conditions. The primary focus is to evaluate the proportion of subjects achieving at least a 75% improvement in the Eczema Area and Severity Index EASI 75 at week 16. During the study, participants will complete regular visits, treatment plans, and laboratory tests as required by the protocol. Researchers will monitor treatment responses and safety through clinical assessments and adherence to the study procedures. The total study duration extends through to August 2027, with continuous evaluation of participants skin condition and treatment outcomes.
CONDITIONS
Brief Title
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Research Team
X
xiaojuan Lai
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here